The technology appraisal of padeliporfin for treating localised prostate cancer (ID866) has been delayed at the request of Steba. NICE has agreed to this request because administration of the padeliporfin requires equipment that is currently not available in the NHS. NICE and Steba are exploring how this can be addressed.